WASHINGTON — The Coalition for a Prosperous America (CPA) praised certain provisions of the National Defense Authorization Act (NDAA), which was passed by both houses of Congress and is expected to be signed into law by President Biden shortly. Those provisions included measures that will increase procurement of domestically manufactured goods and address the growing…
A look at the three largest bills recently circulating in Washington, including the recently passed infrastructure law, and how they’ve gone soft on forced labor. The opportunity presented itself to take the issue more seriously than just another round of studies in each bill mentioned here.
The House Committee on Transportation and Infrastructure expects supply constraints to last into early 2022. Rep. John Garamendi of California highlights “tremendous trade imbalances” as one reason for the bottlenecks, caused by a surge in demand for Asian made goods.
A House Energy and Commerce Committee hearing on clean energy technologies shows division among the parties, with one main agreement: the U.S. will lose out on this market if Washington allows for dependence on Asia for solar, wind and EV battery materials.
Free trade loses out to a bigger government role in securing domestic supply chains of critical medication.
An eye-opening exclusive by the WSJ shows just how much time and energy is being spent by American companies and Silicon Valley venture capitalists investing in semiconductor production…in China. The U.S. needs the CHIPS Act passed this year.
In a House Financial Services Committee hearing on Thursday, Congress appears frustrated in stopping illicit supply chains, and worries about China’s growing resource dominance in high tech and clean tech supply chains.
The Senate Judiciary Committee hears from witnesses on how to combat online-sold counterfeit goods from flooding the U.S. They missed one key remedy — de minimis rulemaking needs a closer look.
A House committee hearing on the impact of the supply crisis on small businesses left out one key solution: import less, make more here.
An Indian drug market that’s been the subject of FDA warnings since 2017 is the apparent source of tainted medication sold in the U.S. and Canada. This is another example as to why we need to reshore critical supply of essential medication. Where is Congress?
